Plasma homocysteine and cardiovascular risk in heart failure with and without cardiorenal syndrome

International Journal of Cardiology

Volumn 141, Issue 1, 2010, Pages 32-38

  Maurer, Michaela ^a   Burri, Sonja ^a   de Marchi, Stefano ^a   Hullin, Roger ^a   Martinelli, Michele ^a   Mohacsi, Paul ^a   Hess, Otto M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cardiorenal syndrome; Cardiovascular risk factors; Heart failure; Homocysteine

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; URIC ACID;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIORENAL SYNDROME; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE CLEARANCE; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RISK FACTORS; SYNDROME;

EID: 77951667552     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.131     Document Type: Article

References (30)

1. Heart Disease and Stroke Statistics - 2009 Update. Circulation 119 (2009) e1-e161
2. Cleland J.G., Khand A., and Clark A. The heart failure epidemic: exactly how big is it?. Eur Heart J 22 (2001) 623-626
3. Swedberg K., Cleland J., Dargie H., Drexler H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
4. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
5. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27 (2006) 65-75
6. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
7. Shah S.H., and Newby L.K. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 11 (2003) 169-179
8. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
9. Jankowska E.A., Ponikowska B., Majda J., et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 115 (2007) 151-155
10. Kuster G.M., Tanner H., Printzen G., Suter T.M., Mohacsi P., and Hess O.M. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly 132 (2002) 623-628
11. Wallen T., Landahl S., Hedner T., Nakao K., and Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 77 (1997) 264-267
12. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
13. Tanner H., Mohacsi P., Fuller-Bicer G.A., et al. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 26 (2007) 622-629
14. Vasan R.S., Beiser A., D'Agostino R.B., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289 (2003) 1251-1257
15. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci 61 (1997) 1205-1215
16. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
17. Andersson A., Lindgren A., and Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 41 (1995) 361-366
18. Jiang X., Yang F., Tan H., et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25 (2005) 2515-2521
19. Bongartz L.G., Cramer M.J., Doevendans P.A., Joles J.A., and Braam B. The severe cardiorenal syndrome: `Guyton revisited'. Eur Heart J 26 (2005) 11-17
20. Heywood J.T. The cardiorenal syndrome: Lessons from the ADHERE database and treatment options. Heart Fail Rev 9 (2004) 195-201
21. McAlister F.A., Ezekowitz J., Tonelli M., and Armstrong P.W. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109 (2004) 1004-1009
22. Dzau V.J. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 31 (1987) 1402-1415
23. Herrmann W., Schorr H., Purschwitz K., Rassoul F., and Richter V. Total homocysteine, vitamin B(12), and total antioxidant status in vegetarians. Clin Chem 47 (2001) 1094-1101
24. Clarke R., and collaborators. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 288 (2002) 2015-2022
25. Pitkin R.M. Folate and neural tube defects. Am J Clin Nutr 85 (2007) 285S-288S
26. Wollesen F., Brattstrom L., Refsum H., Ueland P.M., Berglund L., and Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55 (1999) 1028-1035
27. Friedman A.N., Bostom A.G., Selhub J., Levey A.S., and Rosenberg I.H. The kidney and homocysteine metabolism. J Am Soc Nephrol 12 (2001) 2181-2189
28. Heinecke J.W., Rosen H., Suzuki L.A., and Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262 (1987) 10098-10103
29. Schnyder G., Roffi M., Flammer Y., Pin R., and Hess O.M. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: a randomized controlled trial. JAMA 288 (2002) 973-979
30. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150